Stock listing
Lytix Biopharma Asa
Selected listing: 6BG · FWB · EUR · DE
Lytix Biopharma Asa (Frankfurt:6BG), Health Technology. Latest release Aug 18, 2026: Lytix Biopharma Strengthens Business Development Leadership…
- Ticker
- Frankfurt:6BG
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- Frankfurt
- Currency
- EUR
Latest news from Lytix Biopharma Asa
Lytix Biopharma Strengthens Business Development Leadership with Appointment of Timothy Herpin as Chief Business Officer
August 18, 2026
Lytix Biopharma Reports Phase II Data in Melanoma and Triple-Negative Breast Cancer for Ruxotemitide (LTX-315) in Combination with Pembrolizumab
June 1, 2026
Lytix Biopharma : Financial Document (2026 Q1 Lytix Biopharma Quarterly Presentation Final)
May 21, 2026
Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances
May 21, 2026
Lytix Biopharma ASA to Showcase Promising Phase II Results for Ruxotemitide Combination Therapy at ASCO 2026
April 21, 2026